The Translational and Analytical Chemistry Core (TACC) consists of a Chemistry Core Facility and a Nuclear Magnetic Resonance (NMR) Facility. The Chemistry Core began operations in July 2006 and was designated a CCSG developmental shared resource in July 2008. In 2012, the NMR Facility was moved from the Pharmacology &Analytical Facility to the TACC. The mission of the combined core is to assist researchers with the design, synthesis, and analysis of compounds for use in cancer research. The facility is a state-of-the-art organic chemistry lab, offering services ranging from drug design to pre-clinical drug development. The TACC offers two innovative services that other synthesis cores do not. The molecular modeling service allows design of ab inito new chemical agents. Additionally, the TACC offers small molecule X-ray crystallography. The Chemistry Core has experienced average yearly growth of 36% for design and synthesis services (Development, Modeling, and Custom Synthesis) and a decline of 7% for the analytical services (Mass Spec and X-ray). Over the last 5 years, the Chemistry Core has completed 69 projects and synthesized 144 compounds for 35 cancer center members, representing more than 11,200 hours of service. Major equipment for the Chemistry core includes Varian LC-940 HPLC systems, an Agilent Accurate-Mass TOF LC/MS and a Bruker SMART X2S Automated Bench Top X-ray system. The NMR facility is used primarily for structure determination of compounds developed in drug discovery, pharmacology, and diagnostic imaging laboratories. Other uses include macromolecular structure determination and metabolism studies. Usage of the NMR facility increased 147% over the past five years. Instrumentation consists of Bruker 300 MHz DPX, 500 MHz DRX and 600 MHz Avance NMR spectrometers. In the past five years researchers from thirty-two research groups have utilized the laboratory. Peer reviewed investigators account for 87% of utilization of chemistry services and 46% of utilization of the NMR Facility. For the coming grant cycle, TACC requests $232,209 (24%) support from the CCSG. The institution has provided $1,598,359 for purchase of TACC equipment. Publications cited using the TACC have appeared in J Clin Invest and J Natl Cancer Inst. Future plans include the proposed expansion of the facility to incorporate compound screening to provide for early stage hits and access to GMP capabilities to support clinical research studies. The NMR Facility will continue to support the drug discovery and imaging agent research at MD Anderson, and plans to expand into support of metabolomics research.

Public Health Relevance

The Translational and Analytical Chemistry Core provides the capability to synthesize compounds that otherwise would be difficult and costly to obtain through other sources. Novel compounds can also be designed and synthesized to order against a particular biological target. The NMR facility is used extensively for drug discovery and diagnostic imaging research at MD Anderson.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas MD Anderson Cancer Center
United States
Zip Code
Daver, Naval; Verstovsek, Srdan (2015) Ruxolitinib and DNA methyltransferase-inhibitors: a foray into combination regimens in myelofibrosis. Leuk Lymphoma 56:279-80
Burstein, Matthew D; Tsimelzon, Anna; Poage, Graham M et al. (2015) Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 21:1688-98
Mersch, Jacqueline; Jackson, Michelle A; Park, Minjeong et al. (2015) Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121:269-75
Pugh, Thomas J; Mahmood, Usama; Swanson, David A et al. (2015) Sexual potency preservation and quality of life after prostate brachytherapy and low-dose tadalafil. Brachytherapy 14:160-5
Zuo, Zhuang; Maiti, Sourindra; Hu, Shimin et al. (2015) Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. Mod Pathol 28:373-82
Martin, Neil E; Massey, Laura; Stowell, Caleb et al. (2015) Defining a standard set of patient-centered outcomes for men with localized prostate cancer. Eur Urol 67:460-7
Shen, Qi; Ouyang, Juan; Tang, Guilin et al. (2015) Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response. Eur J Haematol 95:168-76
Massarweh, Nader N; Haynes, Alex B; Chiang, Yi-Ju et al. (2015) Adequacy of the National Quality Forum's Colon Cancer Adjuvant Chemotherapy Quality Metric: Is 4 Months Soon Enough? Ann Surg 262:312-20
Garcia-Manero, Guillermo; Khoury, Hanna J; Jabbour, Elias et al. (2015) A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res 21:985-94
Brown, Alaina J; Sun, Charlotte C; Urbauer, Diana et al. (2015) Targeting those with decreased meaning and peace: a supportive care opportunity. Support Care Cancer 23:2025-32

Showing the most recent 10 out of 2114 publications